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Summary.-112 Tunisian patients with rapidly progressing breast cancer (RPBC)
were entered into a clinical trial evaluating combination chemotherapy as a primary
form of treatment before surgery or radiotherapy. Three cycles of cyclophosphamide,
methotrexate, and 5-fluorouracil (CMF) were administered at monthly intervals;
patients were then randomized to surgery or radiotherapy to control the primary
tumour, and 12 more cycles of CMF followed local/regional therapy. RPBC was
sensitive to CMF; after only 3 cycles, 11%' of evaluable patients showed complete
remission and 78% had at least 250/ diminution in tumour size. The disease-free
interval (DFI) was substantially greater in this series than in a previously reported
series treated by surgery and/or radiotherapy alone. No difference in DFI was found
between patients randomized to receive surgery and those randomized to receive
radiotherapy. Postmenopausal patients responded to CMF as well as premeno-
pausal patients. Combination chemotherapy appears to play an important role in
the control of RPBC, an aggressive malignancy often resembling inflammatory
breast cancer.
OVER THE PAST 10 YEARS we have
reported the high frequency of an acute
form of breast cancer in Tunisia called
rapidly progressing breast cancer (RPBC)
or poussee evolutive (PEV). Characterized
by rapid growth (PEV 1) and/or objective
signs ofinflammation (PEV 2 and PEV 3),
this form has a brief disease-free interval
(DFI) despite vigorous local/regional
treatment. Metastases occur frequently
and manifest the same aggressiveness as
the primary tumour, which explains the
poor prognosis, the 5-year survival being
under 20% (Mourali et al., 1975, 1977;
Tabbane et al., 1977).
Analysis of the natural history sug-
gested that RPBC is mainly a systemic
disease at the outset, needing systemic
treatment to control the disseminated
microfoci, and that local/regional treat-
ment applied to the primary tumour is
inadequate for long-term control. There-
fore, a new study was initiated using
chemotherapy as the major primary
treatment modality and, after considering
the drugs currently used for breast cancer,
a regimen of cyclophosphamide, metho-
trexate and 5-fluorouracil (CMF) was
selected because ofits overall effectiveness
already reported in advanced breast
cancer (Carter, 1980) and its relatively low
toxicity. We further evaluated a series of
parameters, particularly PEV stage, initial
tumour size and menopausal status, to
determine whether any of them were able
to predict initial response to chemo-
therapy and/or length of remission. In
addition to CMF, our therapeutic trial
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included a comparison between radio-
therapy and surgery for local/regional
treatment.
MATERIALS AND METHODS
All patients under the age of 65 seen at the
Institut Salah Azaiz of Tunis between 1
January 1977 and 30 June 1979 were eligible
for this study if their initial visit and subse-
quent evaluation provided evidence ofRPBC
without detectable metastases. After physical
examination and X-rays of the breast, chest
and pelvis, supplemented by other examina-
tions if needed, the patients were staged
according to T, N, M, and PEV criteria as
previously described (Mourali et al., 1975,
1977; Tabbane et al., 1977). The diagnosis of
PEV 1, the mildest form of RPBC, is sub-
jective, determined only by history of rapid
tumour growth without inflammatory signs.
In PEV 2, the inflammation is limited to less
than half the breast, while in PEV 3 inflam-
mation involves more than half the breast.
Once the primary classification was made,
patients underwent a surgical biopsy. If the
tumour was small, it was frequently re-
moved completely. For larger tumours, a
quartier d'orange, including skin, was ob-
tained for histological study. The diagnosis
was made by frozen section, and when cancer
was confirmed, an additional study was
systematically carried out to detect occult
abdominal metastasis; premenopausal
patients were studied atthe timeofoophorec-
tomy and postmenopausal patients were
examined by laparoscopy. All patients aged
less than 65 with no evidence of metastasis
received an explanation of the protocol of
treatment, which included chemotherapy
(CMF) and randomization to surgery or
radiotherapy. Those accepting the protocol
were entered into the study.
The treatment protocol consisted of 3
cycles of CMF, followed by local/regional
treatment with surgery or radiotherapy, and
then 15 more cycles of CMF. The patients
were allocated at random to surgery and
radiotherapy in all cases when local/regional
conditions permitted; in one patient, radio-
therapy was contraindicated because the
tumour was extensively ulcerated.
Under the CMF regimen, patients received
the following at each cycle: oral cyclophos-
phamide, 100 mg/M2 every day from Days 1
to 14, i.v. methotrexate, 40 mg/M2 on Days
1 and 8, and i.v. 5-fluorouracil, 600 mg/M2
on Days 1 and 8. Two weeks of rest were
observed between Day 14 of one cycle and
Day 1 of the next.
WBC and platelet counts were made
before the first and eighth day of each
cycle. The patients' toxicities were graded
from 0 to 2 according to the results of these
counts (Bonadonna et al., 1977) to determint
the dose of CMF as follows:
Grade 0 myelosuppression: The calculated
dose was given.
Grade 1 myelosuppression: 500% of the
calculated dose was given
Grade 2 myelosuppression: No chemo-
therapy was given until the counts
returned to at least Grade 1.
Blood was obtained monthly for routine
chemical assays of serum creatinine, BUN,
calcium, bilirubin, alkaline phosphatase and
SGOT.
After 3 cycles, patients without detectable
metastases were allocated at random to
surgery or radiotherapy for local/regional
treatment. Surgery consisted of radical or
modified radical mastectomy; radiotherapy
was given at a dose of45 Gy, with subsequent
supplementary radiation to the residual
tumour and to any adenopathy. Chemo-
therapy was continued after these local/
regional procedures. During the first 3 cycles
of CMF, each patient had monthly physical
examinations and particular attention was
paid to the tumour size; mammography was
repeated before randomization.
Tumour response was graded as follows:
Complete response (CR): disappearance of
all clinical and radiological evidence of
tumour.
Partial response (PR): more than 50%
reduction in primary tumour size, as
measured by the product of the two
largest perpendicular diameters ofmeas-
urable lesions.
Objective improvement (01): a decrease
in primary tumour size of 25-50%
No response (NR): <25%/ decrease in
primary tumour size, or progression in
disease.
The results of treatment were first
evaluated by the tumour decrease after the
first 3 cycles of CMF. Variables considered as
prognostic for the initial response to chemo-
therapy were those with significantly dif-
ferent distributions among the response
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TABLE 1. Distribution of 112 patients
with rapidly progressing breast cancer
(RPBC) according to their T and N status
TO
PEV1 NO
N1
N2
N3
PEV2 NO
NI
N2
N3 -
PEV3 NO
Ni
N2
N3
Total
1
TI T2
1 10
1 1
-2
1 7
-1
-1
4
-3
T3
2
5
3
2
10
11
1
1
6
13
3
1 3 29 57
T4
1
1
2
1
7
2
14
TM* Total
2 28
J
1
2
2
8
}
39
45
*TM=multiple primaries.
levels from "complete" to "no response".
When the prognostic factor was ordered
(e.g. T of TNM), we looked for trends in the
proportion ofresponders at each factor level.
In addition to the initial effect of chemo-
therapy on tumour size, a preliminary
evaluation of the long-term effect of chemo-
therapy as disease control was determined
by measuring the interval between the first
CMF dose and the first evidence of distant
metastases. In this analvsis a "score test"
(Cox & Hinkley, 1974) was used to see
whether the rates of metastasis per patient
day (assuming exponentiality) differed be-
tween levels of a prognostic factor. Protocol
violations were patients who refused further
treatment, and these are included in all
analyses for the period over which it was
possible to follow them. Of the 31 patients
who did not complete chemotherapy, 24 had
fewer than 5 cycles, and the mean and
median number of cycles were 5 and 3
respectively.
RESULTS
Patient population
Between 1 January 1977 and 30 June
1979, 112 patients entered this study.
Sixty-eight were premenopausal and 44
were postmenopausal. The mean age ofthe
patient group was 45 years (range 25-66).
Staging by TNM (Table I) revealed a high
frequency of large tumours (51% were T3
and 12.5% were T4) and of considerable
regional lymph-node involvement (42%
were N2); all were MO.
Initial response of the primary tumour
to chemotherapy
For the evaluation of the tumour re-
sponse to the first 3 cycles of CMF, 21
patients could not be used because the
entire primary tumour was removed at
the diagnostic biopsy. An additional 2
patients were excluded because they did
not return for a third measurement. One
patient could not be evaluated because
she had no measurable tumour; the
diagnosis had been made on the basis of a
positive biopsy of an axillary lymph node
and a positive cytology from the ipsi-
lateral bleeding nipple.
Of the 88 evaluable patients, 10 (11%)
showed complete response, 45 patients
(51%) had regression >50% (partial
response), 14 (16%) had tumour regres-
sion of 25-50% (objective improvement),
while the remaining 19 (22%) patients did
not respond to treatment (Table II).
The initial response to chemotherapy
was assessed with respect to the patient's
age, the initial pre-treatment tumour size,
TABLE II.-Relationship between PEV stage and response to chemotherapy (88 evaluable
patients)
Menopausal
status
PEV 1
PEV 2
PEV 3
CR PR OI
Pre- Post- Tot.(%) Pre- Post- Tot.(%) Pre- Post- Tot.(%)
2 2 4 (25) 4 3 7 (44) 2 1 3 (19)
2 0 2 (6) 13 8 21 (66) 3 0 3 (9)
3 1 4 (10) 10 7 17 (42) 2 6 8 (20)
10 (11) 45 (51) 14 (16)
NR
Pre- Post- Tot.(%)
- , . 1- 2
5
5
0
1
6
2 (12)
6 (19)
11 (28)
19 (22)
CR =Complete response.
PR =Partial response (> 50%).
OI =Objective improvement (25-50%).
NR=No Response ( < 25% decrease or increase).
Total
16
32
40
88
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TABLE III.-Relationship between initial tumour size and response to chemotherapy
TO+TI
T2
T3
T4
TM
No. (%)
with CR
4 (20)
4 (8)
1 (8)
1 (14)
No. (%)
with PR
12 (60)
23 (48)
5 (38)
5 (72)
No. (%)
with OI
1 (5)
9 (19)
3 (23)
1 (14)
No. (%)
with NR
3 (15)
12 (25)
4 (31)
0 (0)
Total
No.
0
20
48
13
7
the PEV classification, and the meno-
pausal status. The most prominent contri-
butory factor was age, younger patients
being more refractory to treatment; 32%
of patients under age 40 did not respond
to chemotherapy, for example, as com-
pared to 29% of those between 40 and
45, 16% of those between 46 and 50, and
only 5% of those over 51. Tumour regres-
sion was more pronounced in PEVI than
in PEV3, only 2 of 16 (12%) PEVI
patients failing to respond, compared to 11
of 40 (28%) of PEV3 patients (Table II).
Pre-treatment tumour size was also a
factor, large tumours demonstrating less
decrease than small ones (Table III).
Menopausal status did not influence
tumour response (Table II).
Effect of combined treatment (CMF and
local/regional treatment) on length of
remission
For the overall response to therapy, all
112 patients were included in the analysis
while they complied with the chemo-
therapy protocol. Forty-seven patients
completed all 18 cycles of chemotherapy
without developing metastases, 22 devel-
oped metastases during the course of
chemotherapy, 12 were still under treat-
ment free of disease, and 31 were dropped
from the study (30 decided to terminate
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FIG. 1.-The correlation between PEV stage
and metastasis-free interval; 43 PEV3
patients ( 0-) developing metastases
earlier than 28 PEVI ( O-) or 39 PEV2
patients (---A--.) Entire line represents the
total of 112 patients.
treatment and one had to be removed
from the trial because of intractable
cystitis), though they were retained in the
analysis until they left the study. The
overall response to therapy (Fig. 1)
showed that at 2 years the estimated (life
table) proportion of disease-free patients
was 59%. The median disease-free interval
(31 months) compared favourably with
our previous group of patients with PEV
(Tabbane et al., 1977) which showed an
overall median disease-free interval of 18
months. A comparison of the 2 groups by
PEV level revealed an improvement in
disease-free interval for each PEV stage,
TABLE IV.-Comparison of current series with previously reported series*
Median
metastasis-free
(mths)
23* >26
26* 33
16* 19
18* 31
Average
metastasis-free
(mths)
31-7* 85
30*4* 68
26-6* 32
27.8* 51
* Tabbane et al., 1977.
PEV
1
2
3
Total
No. of
cases
21* 28
29* 39
152* 45
202* 112
No. with
metastases
12* 6
14* 11
73* 20
99* 37
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FIG. 2.-90 RPBC patients were treated for
local/regional disease with radiotherapy
(46 pts, -0-) as compared with those
treated with surgery (44 pts, 0-- ...O).
There is no significant difference in
metastasis-free period between treatment.
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FIG. 3.-Relationship between menopausal
status and metastasis-free interval. No dif-
ference was found between premenopausal
(68 pts, ...* ...) and postmenopausal
patients (44 pts, -0-) in their response
to treatment.
but the effect appeared to be less promi-
nent in the PEV 3 category (Table IV).
However, no significance levels can be
attributed to these purely historical com-
parisons.
Of the 112 patients entered into the
study, 90 completed the first 3 cycles of
chemotherapy, and were available for
random allocation to either surgery or
radiotherapy for control of the primary
tumour. Of these 90, 2 were not random-
ized (one refused surgery and received
radiotherapy, while the other had exten-
sive ulceration and required surgery). For
the whole group, no difference in length
ofremission was seen between the patients
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FIG. 4. Relationship between initial tumour
size and metastasis-free interval. There is a
significant difference between patients with
large tumours (T4, 14pts) and those with
small tumours (T2, 29 pts) (P=0-005,
log-rank test). T3 (57 pts) v8 T4 is non-
significant (P= 007).
randomized to surgery and those receiving
radiotherapy (Fig. 2), but in the PEV3
patients there appeared to be a slightly
longer disease-free interval (DFI) in those
randomized to radiotherapy than in those
receiving survery (P= 0.1).
Four factors were evaluated for a
possible relationship to length of remis-
sion: PEV stage; T and N status; initial
response to chemotherapy, and meno-
pausal status. Only menopausal status
was unrelated to DFI (Fig. 3). A severe
PEV grade (Fig. 1) and a large tumour
before chemotherapy (Fig. 4) had a strong
correlation with early metastasis, while
marked lymph-node involvement (N2 or
N3) and a poor initial response to chemo-
therapy had a weaker correlation with
early metastasis. This last association was
mostly noted in PEV3, where mean DFI
(assuming exponential distribution) was:
complete regression, 4 years; > 50%
regression, 3-1 years; <50% regression,
2 1 years; stable or larger, 1-7 years.
Tolerance to chemotherapy
Mild signs of toxicity under the CMF
regimen (alopecia, nausea, vomiting, cys-
titis) were nearly constant. Almost all the
patients received only half-dosages of
CMF at least once because of Grade I
myelosuppression, and 75% received more
Co
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than 10% of their cycles in half-dosages;
50 received more than 50°/0 of their
cycles in half-doses; 20% had one or
several delayed cycles because of Grade II
myelosuppression. Two patients could not
continue CMF therapy because of severe
toxicity one after 10 cycles (haemor-
rhagic cystitis) and one before randomiza-
tion (severe myelotoxicity). Long-term
side effects were minimal, however, and
no fatality or long-term disability could
be attributed to CMF therapy.
DISCUSSION
It is now widely accepted that adjuvant
chemotherapy plays an important role
in the treatment of breast cancer. The
results of numerous clinical trials have
been encouraging and chemotherapy has
significantly improved the prognosis of
breast cancer. This is due to the effective-
ness ofmultiple drug therapy in the control
of disseminated microfoci, and explains
the decrease in clinically detectable
metastases.
Because of the poor results in the con-
trol of RPBC or PEV in our previous
series with local/regional treatment associ-
ated with surgical oophorectomy in pre-
menopausal women, we initiated this
study combining chemotherapy with
treatment of the primary lesion to deter-
mine whether RPBC is sensitive to
chemotherapy and will respond to a com-
bination of systemic and local/regional
treatment.
To the best of our knowledge, however,
there have been no reports of chemo-
therapy as a primary modality in the
treatment of breast cancer, and particu-
larly in RPBC, which includes many cases
of inflammatory breast cancer detected in
our Institute. Whilst other workers have
initiated aggressive chemotherapy proto-
cols for the treatment of inflammatory
breast cancer, their results have not yet
been published.
Before discussing our results, it is
important to note the effect of such a
protocol on our patient population. Com-
pliance in a long chemotherapy protocol
with randomization of treatment of the
primary was difficult for our patients,
particularly those from rural areas. Proto-
col violations were more common in those
randomized to surgery than to radiation,
for example. It is unlikely, however, that
more sophisticated hospital techniques
would have detected earlier metastases
and affected our patient population, even
though 3 patients showed detectable
metastases before randomization. In addi-
tion to X-ray and bone scan, laparotomy
or laparoscopy was used routinely in our
series and we frequently detected occult
metastases by these procedures, which are
not routinely applied by European and
American hospitals. The aggressiveness of
RPBC has provided us with an excellent
indicator of the effectiveness of systemic
chemotherapy. We were not only inter-
ested in the initial decrease in the size of
the primary tumour, but also in prolonga-
tion of survival. Of the parameters that
appeared to be the best predictors of
initial response to chemotherapy, most
important were age, tumour size, and
PEV stage (PEV with prominent inflam-
matory signs generally did poorly).
While we found no difference in remis-
sion length between PEVI and PEV2
patients receiving radiation for control of
the primary tumour and those receiving
surgery, PEV3 patients treated with
radiotherapy did slightly better than those
treated with surgery.
Previous workers have suggested that
both forms of local control involve sig-
nificant risks, particularly because of their
possible depression ofthe immune system.
Primary surgery had been contraindi-
cated in the treatment of PEV at the
Institute Gustave-Roussy (France) where
the PEV classification orig-inated, because
it was considered that surgery would have
an immunosuppressive effect and RPBC
was thought to be the result of initial
patient immunosuppression (Lacour &
Hourtoule, 1967). We have shown in our
previous studies, however, that RPBC is
associated with normal or increased cel-
lular immunity (CMI) to microbial anti-
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gens, chemical sensitizing agents, and
tumour-related antigens (Mourali et al.,
1978; Levine et al., 1981). Stjernsward et
al. (1976) had earlier warned of the pos-
sible risks of radiation-induced immuno-
suppression in the treatment of breast
cancer, but in longitudinal studies on our
patients (unpublished), both delayed
hypersensitivity and in vitro evidence of
CMI have remained intact in patients
receiving surgery or radiotherapy, and
neither regimen appears to offer significant
advantages over the other. Our future
studies will combine both modalities of
treatment according to the areas of
clinical involvement.
Another finding of importance was the
similar response to our protocol in both
pre- and postmenopausal patients. This
was significant not only because it empha-
sized the importance of chemotherapy in
postmenopausal patients who did not have
oophorectomy at the initial staging, but
also because it showed that chemotherapy
can be beneficial in postmenopausal
patients. Bonnadonna et al. (1977) had
previously abandoned the CMF regimen
in postmenopausal patients because of the
poor results in their initial series, but they
suggested that the failures in this group
might have been due to the relatively
short duration (9 cycles) ofchemotherapy.
Our favourable response with 18 cycles
confirms their hypothesis, and prolonged
chemotherapy should be considered in
other clinical trials in postmenopausal
patients.
Although not enough patients have been
followed for long enough for us to deter-
mine the effect on length ofremission and,
ultimately, on survival, the relationship
between decrease in tumour size and the
length of remission, as well as the high
frequency of initial response to chemo-
therapy, suggests to us that chemotherapy
will play an important role in many of our
patients. As seen in Table III, there
already appears to be a significant increase
in the median remission length in our
patients receiving combination therapy
over our initial series.
We are fully aware of the pitfalls in
using historical controls, and we cannot
make firm conclusions as to the long-term
results of our treatment until all patients
in the current group have been followed
for 5 years (a relatively short follow-up is
reasonable in our patients because of the
fulminating nature of the disease in the
vast majority). Our early results are
promising, however, and will form the
basis of future trials using other chemo-
therapeutic agents, an evaluation of the
sequencing of treatment regimens, and
close scrutiny of the variables that deter-
mine the response of our patients to
treatment. This latter parameter, which
has shown us that patients with PEV3,
large tumours and extensive lymph-node
involvement are likely to relapse earlier,
has already demonstrated the need for
more aggressive therapy in these patients.
Furthermore, since we know that - 75%
of patients respond to chemotherapy, we
are evaluating whether an initial debulk-
ing procedure such as that described for
Burkitt's lymphoma (Magrath et al.,
1974) will improve our results, particularly
with the routine use ofradiotherapy in the
treatment of RPBC.
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